Singapore, July 21 -- Menarini Asia-Pacific has announced an exclusive partnership with Pharmacosmos A/S to register, commercialise and distribute Cosela(R) (trilaciclib) across its Asia-Pacific markets.

Chemotherapy-induced myelosuppression (CIM) is a potentially debilitating side effect that damages bone marrow, significantly impacting its hematopoietic function (or its ability to produce healthy blood cells).

For patients with extensive-stage small cell lung cancer (ES-SCLC), chemotherapy remains a cornerstone of treatment, yet it is a major dose limiting complication that can disrupt treatment and compromise outcomes.

Cosela(R) is a first-in-class prophylactic therapy FDA approved to help protect bone marrow from CIM, addressing a ...